AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Jun 29, 2017
35334_dirs_2017-06-29_7d7383f9-8ea0-4ae3-b331-2c6b52673882.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-06-15
Reporting Person: Pascale Adam (CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-15 | Options to buy Common Stock | $0.49 | A | 4738 | Acquired | 2027-06-15 | Common Stock (4738) | Direct |
Footnotes
F1: Amendment due to salary reduction as explained in the 8-K filed on June 22, 2017.